Clinical trials: Cerebral Disorder
Partial Seizures
A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age
This is a study to confirm the efficacy of levetiracetam as adjunctive treatment or as monotherapy in pediatric epilepsy subjects aged 1 month to less than 4 years of age with partial seizures.
- Trial name
- PEACH (NCT03340064)
- Testing
- Levetiracetam
- Where
- 21 sites in Japan
- Volunteers
- 38 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy
Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite
This in an open-label, single dose, fixed sequence, two treatment period study enrolling 8 patients (to obtain 6 evaluable) with end stage renal disease (ESRD) receiving haemodialysis.
- Trial name
- NCT01480609
- Testing
- Retigabine / Ezogabine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Alzheimer Disease
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
This is a Phase Ia/Ib, two-part, randomized, placebo-controlled, double-blinded, first in human(FIH) study to evaluate the safety, tolerability, PK, and PD of ADEL-Y01 in healthy participants in Part 1 and participants with MCI…
- Trial name
- NCT06247345
- Testing
- ADEL-Y01 - healty participants, ADEL-Y01 - MCI/AD
- Where
- 6 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Disease Expert Lab (ADEL), Inc.
Parkinson Disease
FitMi PD Home Therapy for Parkinson's Disease
The investigators will run an at-home usability study of a newly developed home exercise device (FitMi PD) for individuals with Parkinson's disease.
- Trial name
- NCT05655377
- Testing
- FitMi PD
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Flint Rehabilitation Devices, LLC
Epilepsy
MR-Guided Focused Ultrasound in the Treatment of Focal Epilepsy (EP001)
The purpose of this study is to evaluate the feasibility, safety, and initial effectiveness of Exablate thermal ablation of a focal epileptic target area in the brain of patients suffering from medication-refractory epilepsy…
- Trial name
- NCT02804230
- Testing
- Neuro Ablation - Functional
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- InSightec
Stroke
Gait Rehabilitation in Stroke Patients Using Functional Electrical Stimulation and Visual Feedback
recoveriX PRO system is a Brain-Computer Interface (BCI) device that combines Motor Imagination (MI), with Functional Electrical Stimulation (FES) and Virtual Reality (VR) as feedback devices.
- Trial name
- BrainSTEP (NCT07537530)
- Testing
- recoveriX, Control
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- g.tec medical engineering GmbH
Cushing Syndrome
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
- Trial name
- NCT03708900
- Testing
- LCI699
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 12 people
- Sponsor
- RECORDATI GROUP
Subarachnoid Hemorrhage
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
The objective of this feasibility study is to demonstrate the safety and feasibility of using an investigational extracorporeal system and catheter to filter hemorrhagic cerebrospinal fluid (CSF) post subarachnoid hemorrhage…
- Trial name
- PILLAR (NCT02872636)
- Testing
- Spinal catheter insertion with extracorporeal filtration of CSF
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Minnetronix
Alzheimer's Disease
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta amyloid (β-amyloid), a sticky protein in the brain…
- Trial name
- IDENTITY-2 (NCT00762411)
- Testing
- LY450139
- Where
- 91 sites in United States, Brazil and 16 more
- Volunteers
- 1,111 people
- Sponsor
- Eli Lilly and Company
Carotid Artery Calcification, Carotid Artery Diseases
Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)
Prospective, Multi-center, Single-arm Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid…
- Trial name
- NCT07062471
- Testing
- Carotid Intravascular Lithotripsy (IVL)
- Where
- 25 sites in United States
- Volunteers
- 185 people
- Sponsor
- Shockwave Medical, Inc.
Migraine Disorders, Migraine
Prevention Study in Adult Patients Suffering From Migraine Headaches
Purpose of the study is to evaluate dose response relationship, efficacy, safety and tolerability of target doses of GSK1838262 compared to placebo in the prophylactic treatment of migraine headache.
- Trial name
- NCT00742209
- Testing
- GSK1838262
- Where
- 59 sites in United States, Canada
- Volunteers
- 526 people
- Sponsor
- XenoPort, Inc.
Parkinson's Disease
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Doses Administered Using a Divided Dose Approach
- Trial name
- NCT02486432
- Testing
- Levodopa/Carbidopa (Sinemet)
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- NeuroDerm Ltd.
Dravet Syndrome
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).
- Trial name
- NCT07531745
- Testing
- ION337
- Where
- 7 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Migraine, Medication Overuse Headache
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins).
- Trial name
- RESOLUTION (NCT05452239)
- Testing
- Eptinezumab
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 608 people
- Sponsor
- H. Lundbeck A/S
Acute Ischemic Stroke
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
This study tests the drug, Plasmin (Human), in patients with a stroke due to a clot in the middle cerebral artery (MCA). Plasmin is an enzyme that causes clot lysis by cleaving a clot component, fibrin.
- Trial name
- NCT01014975
- Testing
- Plasmin (Human)
- Where
- 23 sites in Australia, Austria and 4 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
Parkinson Disease
Study to Evaluate DNL201 in Subjects With Parkinson's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL201 in subjects with Parkinson's disease.
- Trial name
- NCT03710707
- Testing
- DNL201
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- Denali Therapeutics Inc.
Intracranial Aneurysm, Intracranial Aneurysm, Wide Neck Aneurysm, Large Neck Aneurysm Lesion
Microvention AnEurysm & STroke Real-life Data cOllection
The MAESTRO registry is a post-market, single-arm, non-interventional, multicenter registry
- Conditions
- Intracranial Aneurysm, Intracranial Aneurysm, Wide Neck Aneurysm, Large Neck Aneurysm Lesion, Aneurysmal Subarachnoid Hemorrhage, Ischemic Stroke
- Trial name
- MAESTRO (NCT06494436)
- Testing
- All Microvention Class III implantable device CE marked, All Microvention Mechanical Thrombectomy Class III device CE marked
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Microvention-Terumo, Inc.
Phenylketonuria
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
The primary purpose of this study is to assess the safety and tolerability of AG-181 in subjects with Phenylketonuria (PKU).
- Trial name
- NCT07241234
- Testing
- AG-181
- Where
- 5 sites in United States, Poland
- Volunteers
- 20 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Epilepsy
RNS® System LTT Study
The RNS® System LTT study is designed to assess the ongoing safety and to evaluate the long-term efficacy of the RNS® System as an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age or older…
- Trial name
- NCT00572195
- Testing
- RNS® System
- Where
- 33 sites in United States
- Volunteers
- 230 people
- Sponsor
- NeuroPace
Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF).
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS
- Trial name
- NCT06683612
- Testing
- PIPE-791
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.